Small tyrosine kinase inhibitors as key molecules in the expression of metalloproteinases by solid tumors

Connective Tissue Research

Volumn 49, Issue 3-4, 2008, Pages 211-214

  Stahtea, Xanthi N ^a   Kousidou, Olga Ch ^a   Roussidis, Andreas E ^a   Tzanakakis, George N ^b   Karamanos, Nikos K ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b UNIVERSITY OF CRETE   (Greece)

Author keywords

Breast Cancer; Colon Cancer; Genistein; Imatinib (Gleevec); Metalloproteinases; Tyrosine Kinase Inhibitor

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; ADENOSINE TRIPHOSPHATE; ALPHA (3,4 DIMETHOXYBENZYLIDENE) 2 PYRIDYLACETONITRILE; CD147 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIGALLOCATECHIN GALLATE; ERBSTATIN; ERLOTINIB; ESTROGEN RECEPTOR; GEFITINIB; GELATINASE A; GELATINASE B; GENISTEIN; HERBIMYCIN A; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERSTITIAL COLLAGENASE; LAVENDUSTIN A; MATRILYSIN; METALLOPROTEINASE; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UROKINASE;

ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CELL ADHESION; CELL GROWTH; CELL INTERACTION; CELL INVASION; CELL MIGRATION; DRUG DOSE REGIMEN; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; HUMAN; LOW DRUG DOSE; METASTASIS; NONHUMAN; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; REVIEW; SOLID TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; HUMANS; METALLOPROTEASES; NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 48649095593     PISSN: 03008207     EISSN: 16078438     Source Type: Journal    
DOI: 10.1080/03008200802143307     Document Type: Review

References (28)

1. Hood, J. D. and Cheresh, D. A. (2002) Role of integrins in cell invasion and migration. 2, pp. 91-100.
2. Roussidis, A. E., Theocharis, A. D., Tzanakakis, G. N. and Karamanos, N. K. (2007) The importance of c-kit and PDGF receptors as potential targets for molecular therapy in breast cancer. 14, pp. 735-743.
3. Kolibaba, K. S. and Drucker, B. J. (1997) Protein tyrosine kinases and cancer. 9:13333, pp. F217-F248.
4. Kohn, E. and Liotta, L. (1995) Molecular insights into cancer invasive strategies for prevention and intervention. 55, pp. 1856-1862.
5. Nicholson, R. I., Gee, J. M. and Harper, M. E. (2001) EGFR and cancer prognosis. 37, pp. S9-S15.
6. Rusnak, D. W., Affleck, K. Cockerill, S. G. et al. (2001) The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. 61, pp. 7196-7203.
7. Levitzki, A. (1992) Tyrphostins: Tyrosine kinase blockers as novel antiproliferative agents and dissectors of signal transduction. 6:14, pp. 3275-3582.
8. Roussidis, A. E., Mitropoulou, T. N., Theocharis, A. D., Kiamouris, C., Papadopoulos, S., Kletsas, D. and Karmanos, N. K. (2004) STI571 as a potent inhibitor of growth and invasiveness in human epithelial breast cancer cells. 2, p. 1445.
9. Lin, N. U. and Winer, E. P. (2004) New targets for therapy in breast cancer: Small molecule tyrosine kinase inhibitors. 6:5, pp. 204-210.
10. Razandi, M., Pedram, A., Park, S. T. and Levin, E. R. (2003) Proximal events in signaling by plasma membrane estrogen receptors. 278:4, pp. 2701-2712.
11. Seta, K., Nanamori, M., Modrall, J. G., Neubig, R. R. and Sadoshima, J. (2002) AT1 receptor mutant lacking heterotrimeric G protein coupling activates the Src-Ras-ERK pathway without nuclear translocation of ERKs. 277, pp. 9268-9277.
12. Hazzalin, C. A. and Mahadevan, L. C. (2002) MAPK-regulated transcription: A continuously variable gene switch?. 3, pp. 30-40.
13. Rosenthal, E. L., Johnson, T. M., Allen, E. D., Apel, I. G., Punturieri, A. and Weiss, S. J. (1998) Role of the plasminogen activator and matrix metalloproteinase systems in epidermal growth factor- and scatter factor-stimulated invasion of carcinoma cells. 58, pp. 5221-5230.
14. Guo, H., Zucker, S., Gordon, M. K., Toole, B. P. and Biswas, C. (1997) Stimulation of matrix metalloproteinase production by recombinant extracellular matrix metalloproteinase inducer from transfected Chinese hamster ovary cells. 272, pp. 24-27.
15. Kanekura, T., Chen, X. and Kanzaki, T. (2002) Basigin (CD147) is expressed on melanoma cells and induces tumor cell invasion by stimulating production of matrix metalloproteinases by fibroblasts. 99, pp. 520-528.
16. Menashi, S., Serova, M., Ma, L., Vignot, S., Mourah, S. and Calvo, F. (2003) Regulation of extracellular matrix metalloproteinase inducer and matrix metalloproteinase expression by amphiregulin in transformed human breast epithelial cells. 63:22, pp. 7575-7580.
17. Price, D. J., Avraham, S., Feuerstein, J., Fu, Y. and Avraham, H. K. (2002) The invasive phenotype in HMT-3522 cells requires increased EGF receptor signaling through both PI 3-kinase and ERK 1, 2 pathways. 9, pp. 87-102.
18. Reddy, K. B., Krueger, J. S., Kondapaka, S. B. and Diglio, C. A. (1999) Mitogen-activated protein kinase (MAPK) regulates the expression of progelatinase B (MMP-9) in breast epithelial cells. 82, pp. 268-273.
19. Sun, J. and Hemler, M. E. (2001) Regulation of MMP-1 and MMP-2 production through CD147/extracellular matrix metalloproteinase inducer interactions. 61, pp. 2276-2281.
20. Caceres, M., Guerrero, J. and Martinez, J. (2005) Overexpression of RhoA-GTP induces activation of the epidermal growth factor receptor, dephosphorylation of focal adhesion kinase and increased motility in breast cancer cells. 10:3091, pp. 229-238.
21. Kousidou, O.Ch., Roussidis, A. E., Theocharis, A. D. and Karamanos, N. K. (2004) Expression of MMPs and TIMPs genes in human breast cancer epithelial cells depends on cell culture conditions and is associated with their invasive potential. 24, p. 4025.
22. Kousidou, O.Ch., Mitropoulou, T. N., Roussidis, A. E., Kletsas, D., Theocharis, A. D. and Karamanos, N. K. (2005) Genistein suppresses the invasive potential of human breast cancer cells through transcriptional regulation of metalloproteinases and their tissue inhibitors. 26, p. 1101.
23. Kousidou, O.Ch., Tzanakakis, G. N. and Karamanos, N. K. (2006) Effects of the natural isoflavonoid genistein on growth, signaling pathways and gene expression of matrix macromolecules by breast cancer cells. 6, pp. 331-337.
24. Saaristo, A., Karpanen, T. and Alitalo, K. (2000) Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis. 19, pp. 6122-6129.
25. Masuda, M., Suzui, M. and Weinstein, I. B. (2001) Effects of epigallocatechin-3-gallate on growth, epidermal growth factor receptor signaling pathways, gene expression and chemosensitivity in human head and neck squamous cell carcinoma cell lines. 7:12, pp. 4220-4229.
26. Shimizu, M., Deguchi, A., Hara, Y., Moriwaki, H. and Weinstein, I. B. (2005) EGCG inhibits activation of the insulin-like growth factor-1 receptor in human colon cancer cells. 334, pp. 947-953.
27. Stahtea, X. N., Roussidis, A. E., Kanakis, I., Tzanakakis, G. N., Chalkiadakis, G., Mavroudis, D., Kletsas, D. and Karamanos, N. K. (2007) Imatinib inhibits colorectal cancer cell growth and suppresses stromal-induced growth stimulation, MT1-MMP expression and pro-MMP2 activation. 121:12, pp. 2808-2814.
28. Toda, D., Ota, T., Tsukuda, K., Watanabe, K., Fujiyama, T., Murakami, M., Naito, M. and Shimizu, N. (2006) Gefitinib decreases the synthesis of matrix metalloproteinase and the adhesion to extracellular matrix proteins of colon cancer cells. 26:1, pp. 129-134.